Pseudobulbar affect in multiple sclerosis: Toward the development of innovative therapeutic strategies

Journal of the Neurological Sciences

Volumn 245, Issue 1-2, 2006, Pages 153-159

  Miller, Ariel ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

Affect; Crying; Emotion; Laughing; Multiple sclerosis; Pseudobulbar affect

Indexed keywords

AMANTADINE; AMITRIPTYLINE; CITALOPRAM; DEXTROMETHORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; LEVODOPA; NORTRIPTYLINE; PAROXETINE; PLACEBO; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CRYING; DEMENTIA; DIZZINESS; EMOTION; EPIGASTRIC DISCOMFORT; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INCIDENCE; MENTAL DISEASE; MULTIPLE SCLEROSIS; NAUSEA; NERVE CELL NETWORK; NONVERBAL COMMUNICATION; PRIORITY JOURNAL; PSEUDOBULBAR PALSY; SEXUAL DYSFUNCTION; STROKE; TACHYCARDIA; TRAUMATIC BRAIN INJURY; URINE RETENTION; VOMITING; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; DEXTROMETHORPHAN; EMOTIONS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MOOD DISORDERS; MULTIPLE SCLEROSIS; QUINIDINE;

EID: 33646922845     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2005.09.018     Document Type: Article

References (38)

1. Lieberman A., and Benson D.F. Control of emotional expression in pseudobulbar palsy. A personal experience. Arch Neurol 34 11 (1977) 717-719
2. Darwin C. The expression of the emotions in man and animals (1872), D Appleton and Company, New York
3. Feinstein A., Feinstein K., Gray T., and O'Connor P. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 54 9 (1997) 1116-1121
4. Poeck K. Pathological laughing and weeping in patients with progressive balbar palsy. Ger Med Mon 14 8 (1969) 394-397
5. Huffman J.C., and Stern T.A. Poststroke neuropsychiatric symptoms and pseudoseizures: a discussion. Prim Care Companion J Clin Psychiat 5 2 (2003) 85-88
6. House A., Dennis M., Molyneux A., Warlow C., and Hawton K. Emotionalism after stroke. BMJ 298 6679 (1989) 991-994
7. Dark F.L., McGrath J.J., and Ron M.A. Pathological laughing and crying. Aust N Z J Psychiatry 30 4 (1996) 472-479
8. Arciniegas D.B., and Topkoff J. The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. Semin Clin Neuropsychiatry 5 4 (2000) 290-306
9. Morris P.L., Robinson R.G., and Raphael B. Emotional lability after stroke. Aust N Z J Psychiatry 27 4 (1993) 601-605
10. Wilson S.A.K. Some problems in neurology. II: Pathological laughing and crying. J Neurol Psychopathol IV (1924) 299-333
11. Ironside R. Disorders of laughter due to brain lesions. Brain 79 4 (1956) 589-609
12. Caroscio J.T., Mulvihill M.N., Sterling R., and Abrams B. Amyotrophic lateral sclerosis. Its natural history. Neurol Clin 5 1 (1987) 1-8
13. Gallagher J.P. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 80 2 (1989) 114-117
14. Starkstein S.E., Migliorelli R., Teson A., Petracca G., Chemerinsky E., Manes F., et al. Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. J Neurol Neurosurg Psychiatry 59 1 (1995) 55-60
15. Parvizi J., Anderson S.W., Martin C.O., Damasio H., and Damasio A.R. Pathological laughter and crying: a link to the cerebellum. Brain 124 Pt 9 (2001) 1708-1719
16. Robinson R.G., Parikh R.M., Lipsey J.R., Starkstein S.E., and Price T.R. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 150 2 (1993) 286-293
17. Tateno A., Jorge R.E., and Robinson R.G. Pathological laughing and crying following traumatic brain injury. J Neuropsychiatry Clin Neurosci 16 4 (2004) 426-434
18. Moore S.R., Gresham L.S., Bromberg M.B., Kasarkis E.J., and Smith R.A. A self report measure of affective lability. J Neurol Neurosurg Psychiatry 63 1 (1997) 89-93
19. Smith R.A., Berg J.E., Pope L.E., Callahan J.D., Wynn D., and Thisted R.A. Validation off CNS emotional liability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler 10 (2004) 1-7
20. Udaka F., Yamao S., Nagata H., Nakamura S., and Kameyama M. Pathologic laughing and crying treated with levodopa. Arch Neurol 41 10 (1984) 1095-1096
21. Schiffer R.B., Herndon R.M., and Rudick R.A. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 312 23 (1985) 1480-1482
22. Andersen G., Vestergaard K., and Riis J.O. Citalopram for post-stroke pathological crying. Lancet 342 8875 (1993) 837-839
23. Burns A., Russell E., Stratton-Powell H., Tyrell P., O'Neill P., and Baldwin R. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 14 8 (1999) 681-685
24. Muller U., Murai T., Bauer-Wittmund T., and von Cramon D.Y. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 13 10 (1999) 805-811
25. Baldessarini R.J. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics (2001), The McGraw-Hill Companies, Inc., New York 447-483
26. Pollock B.G., Mulsant B.H., Nebes R., Kirshner M.A., Begley A.E., Mazumdar S., et al. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 155 8 (1998) 1110-1112
27. Tortella F.C., Pellicano M., and Bowery N.G. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 10 12 (1989) 501-507
28. Pope L.E., Khalil M.H., Berg J.E., Stiles M., Yakatan G.J., and Sellers E.M. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol 44 10 (2004) 1132-1142
29. Maurice T., and Lockhart B.P. Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry 21 1 (1997) 69-102
30. Musacchio J.M., Klein M., and Canoll P.D. Dextromethorphan and sigma ligands: common sites but diverse effects. Life Sci 45 19 (1989) 1721-1732
31. Zhang Y., Britto M.R., Valderhaug K.L., Wedlund P.J., and Smith R.A. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 51 6 (1992) 647-655
32. Brooks B.R., Thisted R.A., Appel S.H., Bradley W.G., Olney R.K., Berg J.E., et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 63 8 (2004) 1364-1370
33. Benedict R.H., Carone D.A., and Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging 14 3 Suppl (2004) 36S-45S
34. Zivadinov R., and Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 14 3 Suppl (2004) 27S-35S
35. Matthews P.M. An update on neuroimaging of multiple sclerosis. Curr Opin Neurol 17 4 (2004) 453-458
36. Pratt R.T. An investigation of the psychiatric aspects of disseminated sclerosis. J Neurochem 14 4 (1951) 326-335
37. Surridge D. An investigation into some psychiatric aspects of multiple sclerosis. Br J Psychiatry 115 524 (1969) 749-764
38. Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, et al. Randomized trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol in press; 59(5).